Sano

Founded in Wellesley, Massachusetts, Sano is dedicated to developing a Point of Care diagnostic platform aimed at the early detection and intervention of at least six different diseases affecting both human and veterinary populations. Their primary focus is on chronic wounds such as diabetic foot ulcers and venous leg ulcers, with the goal of personalizing treatment to promote faster healing and significantly reduce treatment costs. Sano leverages proprietary chemistry and has developed prototypes, with plans to commence clinical trials soon.

Sano's team includes notable experts in the fields of diagnostics and medical technology. The company has garnered interest from investors focused on innovative healthcare solutions. Among its key achievements are the successful testing of its proprietary chemistry and the design of functional prototypes. Sano's impact lies in its potential to transform chronic wound care, improving patient outcomes and reducing healthcare expenses by minimizing trial-and-error treatments.